Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.11% | -74.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.11% | -74.51% | |||
| Cost of Revenue | -3.90% | 8.49% | |||
| Gross Profit | 5.56% | -372.72% | |||
| SG&A Expenses | 7.18% | 10.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.52% | 8.83% | |||
| Operating Income | 2.34% | -157.79% | |||
| Income Before Tax | 8.61% | -276.66% | |||
| Income Tax Expenses | -93.66% | 1,258.14% | |||
| Earnings from Continuing Operations | 10.05% | -281.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.05% | -281.32% | |||
| EBIT | 2.34% | -157.79% | |||
| EBITDA | 2.41% | -172.87% | |||
| EPS Basic | 10.64% | -280.61% | |||
| Normalized Basic EPS | 1.10% | -245.27% | |||
| EPS Diluted | 11.07% | -273.63% | |||
| Normalized Diluted EPS | 1.10% | -245.27% | |||
| Average Basic Shares Outstanding | 0.65% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.65% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||